FIRST exclusively enrolled in the U.S, compared to START where only 20% were from the U.S. Additionally, individuals in FIRST were more advanced in their HIV infection than START participants (with substantially lower CD4+ T-cell count and higher HIV-VL at study entry). The gene discussed is CD4; the disease is HIV infectious disease.